baya de aronia

Chokeberry (Aronia melanocarpa): A Comprehensive Reference

1. Identity and Botanical Classification

1.1 Taxonomy and Species

Aronia is a genus of deciduous shrubs, the chokeberries, in the family Rosaceae, native to eastern North America and most commonly found in wet woods and swamps. The genus Aronia is considered to have three species. The most common and widely used is Aronia melanocarpa (black chokeberry), which emerged from Eastern North America. The lesser known Aronia arbutifolia (red chokeberry) and the hybrid form Aronia prunifolia (purple chokeberry) were first cultivated in Central and Eastern North America.

Black aronia or chokeberry (Aronia melanocarpa L.) is a shrub plant of the family Rosaceae. Native to wetlands, swamps, and moist woodlands from New England south to the Carolinas, black chokeberry has gained recognition as one of the most versatile native shrubs available, tolerating everything from periodically flooded soils to drought conditions once established.

The black aronia species contains higher levels of anthocyanins than purple (Aronia prunifolia) or red aronia (Aronia arbutifolia), whereas red and purple aronia are richer in phenolic acid and proanthocyanins. These differences in phytochemical profile are significant for commercial and nutraceutical applications, with A. melanocarpa being the predominant species in scientific research and supplementation.

In the eighteenth century, the first shrubs of the best-known species Aronia melanocarpa reached Europe, where they were first cultivated in Scandinavia and Russia. Black chokeberry is grown as a common shrub in Central Europe, where it is mainly used for food production.

1.2 Common Names and Nomenclature

The plant is commonly called "black chokeberry," "aronia berry," or simply "aronia." The sharp taste of the fresh fruit dries out the mouth, earning the plant the nickname "chokeberries." Chokeberries are frequently confused with chokecherries; aronia berries and chokecherries both contain polyphenolic compounds such as anthocyanins, yet the two plants are somewhat distantly related within the Amygdaloideae subfamily.

1.3 Common Forms and Preparations

Fresh, unprocessed chokeberry fruits are rarely consumed due to their astringent taste, but they are used in the food industry for the production of juices, nectars, syrups, jams, preserves, wines, tinctures, fruit desserts, jellies, fruit teas, and dietary supplements.

An aronia wine is made in Lithuania and Minnesota. The berries were traditionally used in pemmican. In Poland, aronia berries are added to jams and juices or dried to make an herbal tea, sometimes blended with other ingredients such as blackcurrant. Aronia is also used as a flavoring or colorant for beverages or yogurts. In supplemental contexts, the berry is available in standardized dry extract form, as fruit powder, as encapsulated preparations, and as concentrated juice.

Black chokeberry (Aronia melanocarpa) fruits are among the richest sources of polyphenols and anthocyanins in the plant kingdom and suitable raw material for production of functional foods. Both dried and fresh black chokeberries are available; the dried berries last up to a year in dry storage. Fresh chokeberries are highly perishable, like most berries.

2. Traditional and Historical Use

2.1 Indigenous North American Use

Black chokeberry has a rich history of use by Indigenous peoples throughout eastern North America. Various tribes, including the Ojibwe, Potawatomi, and Cherokee, harvested the berries for food and medicine.

Traditionally, Potawatomi Native Americans used black chokeberry to treat colds, coughs, and fever. Native Americans traditionally used every part of the plant—for nutrition, dyeing materials, curing meats, and medicinal purposes.

Native to North America and used for many purposes by Native American cultures, the "chokeberry" was named by early European settlers due to its tart, astringent taste. Once used for everything from medicinal teas, to dyes, to curing meats, to dried nutritional treats in long winter months for Native American tribes, the berry was driven into relative obscurity in North America due to urbanization and the commercialization of U.S. agriculture during the 20th century.

2.2 European Adoption and Food Traditions

After its introduction to Europe in the eighteenth century, black chokeberry gained particular popularity in Eastern Europe, especially Poland, Russia, and the Scandinavian countries, where it was cultivated for food production and folk medicine. In Bosnia and Herzegovina, the berries are sold fresh and frozen or made into juices, jams, and teas. Aronia berries have been consumed as food and as a folk remedy in Eastern Europe for centuries, and commercially in Germany and Poland for over two decades.

3. Key Constituents and Active Compounds

3.1 Polyphenol Profile

Polyphenols are biofactors that determine the high bioactivity of chokeberries — some of the richest sources of polyphenols — which include anthocyanins, proanthocyanidins, flavonols, flavanols, and phenolic acids.

Analysis of polyphenols in chokeberries has identified the following individual chemicals (among hundreds known to exist in the plant kingdom): cyanidin-3-galactoside, cyanidin-3-arabinoside, quercetin-3-glycoside, epicatechin, caffeic acid, delphinidin, petunidin, and pelargonidin.

Chokeberries are particularly rich in proanthocyanidins, anthocyanins, and hydroxycinnamic acids. The total polyphenol content of aronia fruits varied between 1022 mg/100 g fresh weight and 1795 mg/100 g fresh weight, and ORAC antioxidant activity from 109 µmol TE/g to 191 µmol TE/g fresh weight.

Phenolic acids constitute 7.5% of chokeberry polyphenols, with chlorogenic acid being the primary compound detected in the fruit. Chokeberries mostly contain chlorogenic and neochlorogenic acids. Other phenolic acids include cryptochlorogenic acid, p-coumaric acid and its derivatives, caffeic acid and its derivatives, protocatechuic, vanillic, ferulic, salicylic, syringic, 4-hydroxybenzoic, and ellagic acids.

Cyanidin-3-O-galactoside from Aronia melanocarpa exhibited significantly higher antioxidant capacity compared to other individual anthocyanins.

3.2 Other Nutritional Constituents

Aronia contains many different bioactive compounds, including phenolic compounds, terpenoids, lipids, organic acids, vitamins, sterols, and other substances, which collectively contribute to its multiple physiological activities and health benefits.

Sorbitol was found to be the main carbohydrate of fresh aronia fruits. Organic acids were represented by substantial amounts of quinic acid (average content 404.4 mg/100 g fresh weight), malic acid (328.1 mg/100 g fresh weight), and ascorbic acid (65.2 mg/100 g fresh weight). Shikimic acid, citric acid, oxalic acid, and succinic acid were found as minor components.

Phenolic compounds such as anthocyanins, cyanidins, phenolic acids, proanthocyanidins, triterpenoids, and their analogues have been identified as the major active components of aronia berries.

3.3 Phytochemical Variation and Processing Effects

The plant produces these pigments mainly in the leaves and skin of the berries to protect the pulp and seeds from constant exposure to ultraviolet radiation and production of free radicals. By absorbing UV rays in the blue-purple spectrum, leaf and skin pigments filter intense sunlight, serve antioxidant functions, and thereby have a role assuring regeneration of the species.

Anthocyanins are sensitive to pH, light, and temperature, reducing their effectiveness in processed forms like juices or supplements. This is a material consideration in evaluating the bioactivity of commercially available preparations relative to fresh fruit.

4. Established Mechanisms of Action

4.1 Antioxidant Mechanisms

Aronia seems to exert its antioxidant effect through direct and indirect actions, offering wide protection of the cell against different sources of oxidative stress. These effects can take place in the cells or cytosol by both the direct inhibition of reactive oxygen species (ROS), or by activation of antioxidant enzymes (catalase, superoxide dismutase, glutathione peroxidase).

According to the literature, black chokeberry Aronia melanocarpa exhibits strong antioxidant properties. The mechanisms underlying these properties are multifaceted, involving the enhancement and protection of enzymes such as paraoxonase, superoxide dismutase (SOD), and glutathione.

Research has shown that Aronia melanocarpa constituents can accumulate at the lipid bilayer-aqueous phase interface in erythrocyte membranes. Their localization within the hydrophilic region of the membrane creates a protective barrier against free radicals, thereby enhancing the effectiveness and safety of these antioxidants.

4.2 Anti-inflammatory Mechanisms

Anthocyanins in black chokeberry play a significant role in modulating inflammation. This regulatory effect is attributed to their ability to bind iron and regulate various immune system components involved in inflammatory processes. The anti-inflammatory properties of black chokeberry are intricately linked to the enhancement of the human immune response, involving the suppression of pro-inflammatory cytokines and the release of anti-inflammatory cytokines.

In vitro, following pretreatment with an anthocyanin-enriched aronia bioactive fraction at 10–25 µg/mL, human bronchial epithelial cells exposed to LPS showed significantly decreased mRNA expression of TNF-α, IL-6, IL-8, RANTES, IL-1β, and COX-2. The same fraction attenuated the secretion of TNF-α, IL-6, IL-8, and RANTES protein.

Supporting evidence from animal and cellular models highlights the regulation of NF-κB and AMPK signaling pathways, modulation of gut microbiota, and protective effects against metabolic and age-related disorders.

4.3 Gut Microbiota Interaction and Bioavailability

The bioavailability of anthocyanins is significantly modulated by extensive metabolism conducted by gut microbiota in the colon. This complex metabolic process produces a diverse spectrum of low molecular weight phenolic metabolites, which exhibit enhanced bioavailability and superior absorption rates.

Polyphenols have a bidirectional interaction with the gut microbiota. In addition to the microbes' enzymatic breakdown of the dietary components, polyphenols act as prebiotics. They nourish the bacteria and promote the growth of certain bacterial strains and thus modulate the microbial composition, which further promotes the immune system through modulation of metabolism, integrity, and immune function of enterocytes.

The most abundant polyphenols in aronia, namely proanthocyanidins (PACs), anthocyanins, and phenolic acids, exhibit low intestinal absorption. This low absorption is why gut-microbial transformation of these compounds into smaller phenolic metabolites is considered so important to the observed physiological effects.

4.4 Enzyme Inhibition Relevant to Glycemic Control

In vitro and animal studies have shown that anthocyanins are effective carbohydrate digestive enzyme inhibitors. These mechanisms play a role in their anti-diabetic properties by reducing postprandial blood glucose levels. Both anthocyanins and acarbose (a known anti-diabetic medication) target α-glucosidase and pancreatic α-amylase breakdown, reducing the amount of glucose released into the bloodstream.

One study emphasized that the 3-caffeoylquinic acid and 4-caffeoylquinic acid compounds present in aronia juice can inhibit both α-glucosidase and dipeptidyl peptidase IV (DPP-IV) activity; the IC50 values of these compounds against DPP-IV were 0.19 and 0.05 µmol, respectively, and they were thought to contribute significantly to the improvement of type 2 diabetes mellitus.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health

Blood Pressure

The evidence from randomized controlled trials (RCTs) on chokeberry and cardiometabolic outcomes remains inconclusive. A systematic review and meta-analysis aimed to assess the effects of chokeberry supplementation on cardiometabolic outcomes, including anthropometric parameters, glycemic control, lipid profile, and blood pressure in adults.

A meta-analysis of controlled trials evaluated the effects of daily aronia berry supplementation for an average of 6–8 weeks on the outcomes of total cholesterol and blood pressure. Three distinct analyses were conducted for systolic blood pressure, diastolic blood pressure, and total cholesterol. Daily supplementation with aronia berry extracts for 6–8 weeks significantly reduced systolic blood pressure, which is a key risk factor for cardiovascular disease.

An earlier clinical study in patients with metabolic syndrome used aronia extract at 25 patients with metabolic syndrome treated with aronia extract (3 × 100 mg/day) for two months. Aronia extract was found to be of benefit to patients with metabolic syndrome, seeming to result from the influence of anthocyanins and possibly other flavonoids on blood pressure, serum level of endothelin-1 (ET-1), lipids, and oxidative status (GSH-Px, SOD, TBARS).

However, a systematic review assessing 17 studies on cardiometabolic risk factors found a more mixed picture: aronia did not influence body weight, circulating triglycerides, total cholesterol, HDL cholesterol, or blood pressure in the subset of studies amenable to quantitative analysis. Despite the existing limitations, human clinical trials on chokeberry supplementation have suggested potential cardiometabolic health benefits, particularly in improving blood pressure and lipid profiles; however, the findings are inconsistent.

Lipid Profile

Middle-aged non-medicated subjects with metabolic syndrome (n = 38) and 14 healthy volunteers were included in a published clinical study. Patients with metabolic syndrome were treated with 100 mg of aronia melanocarpa extract (AM) three times daily for 2 months. A significant reduction in total cholesterol, LDL-C, and triglycerides was observed after AM supplementation. Beneficial changes in coagulation parameters were also observed. After 1 month of AM administration, there was significant inhibition of platelet aggregation.

One study tested the effect of three daily doses of 50 mL aronia juice, corresponding to 258 mg anthocyanins, for three months and compared the results to no supplementation in 35 type 2 diabetes mellitus patients. A significant reduction in LDL cholesterol after aronia supplementation was observed, but only non-significant reductions in fasting blood glucose, HbA1c, total cholesterol, and triglycerides were found.

Platelet Function and Hemostasis

Metabolic syndrome is characterized by central obesity, impaired glucose tolerance, dyslipidemia, and hypertension. It is associated with non-traditional cardiovascular disease risk factors such as inflammatory processes, disorders of coagulation and fibrinolysis, and platelet hyperactivity. The use of natural supplements rich in plant polyphenols represents one strategy for addressing these factors. Aronia melanocarpa berries are one example of a natural source of pharmacologically relevant substances.

Evidence strength: The cardiovascular evidence is based on small-to-moderate sized clinical trials and meta-analyses. While some analyses indicate statistically significant effects on blood pressure and lipids, findings across studies are inconsistent, and the overall quality and size of the evidence base is limited. Larger, well-controlled RCTs are needed to confirm these effects.

5.2 Antioxidant and Anti-inflammatory Effects

The antioxidant activity of aronia berries has been investigated in a clinical trial on 11 healthy human volunteer subjects who drank daily 250 mL of the juice of aronia berries for three weeks. The serum antioxidant capacity of the participants was increased significantly when tested by a spectrophotometric method using DPPH stable radical cations.

However, a subsequent clinical trial investigation indicated that consumption of aronia berries did not change the biomarkers of oxidative stress and the total antioxidant activity measured in both plasma and urine of the participants when a 12-week, randomized, placebo-controlled trial was conducted on 49 healthy adult former smokers who consumed daily 500 mg of the ethanolic extract of aronia berries.

Human intervention trials have shown improved antioxidant status, lipid and glucose metabolism, vascular function, and inflammatory markers. However, some results remain inconclusive due to differences in cultivar, processing, dosage, and individuals.

One study reported that the daily consumption of 150 mL of aronia juice by rowers engaged in physical exercise during a 1-month training camp reduced exercise-induced oxidative damage to red blood cells.

Evidence strength: In vitro and animal data for antioxidant and anti-inflammatory activity are robust. Human evidence is mixed, with some trials showing significant improvements in oxidative stress and inflammatory markers and others finding no significant effect, particularly in healthy populations without elevated baseline oxidative stress.

5.3 Glycemic Control and Metabolic Syndrome

A randomized, controlled, double-blinded, parallel intervention trial was conducted using 14 human subjects who ingested either 0 mL or 100 mL of aronia juice daily for 30 days. Anthropometric measurements, fasting, and postprandial measures of glucose and lipid metabolism and inflammation, 16S rRNA fecal microbial composition data, and metabolomic data were collected. Daily consumption of aronia prevented a rise in cholesterol levels (β = −0.50, p = 0.03) and reduced postprandial glucose (β = −3.03, p < 0.01).

Clinical experiments have demonstrated that A. melanocarpa juice can effectively lower fasting blood glucose levels in patients with type 2 diabetes.

A meta-analysis of controlled clinical trials showed that daily supplementation with an extract of aronia berries for six to eight weeks significantly reduced systolic blood pressure and total cholesterol of adult participants — the main factors for cardiovascular disease risk. After a one-month supplementation with a commercial extract of aronia berries in patients with metabolic syndrome, the overall potential for coagulation, clot formation, and fibrinolysis were found to be decreased significantly, with blood pressure, glycemia, and the lipid profile all being reduced.

In a small pilot intervention study with only ten volunteers, phenolic extracts prepared from aronia juice were tested against peripheral glucose and blood glucose levels after the intake of a drink containing these extracts plus maltodextrin and water. In all ten volunteers, the intake of aronia extract (100 mg) reduced both the peripheral glucose and the blood glucose levels significantly.

Evidence strength: Preliminary and promising for blood glucose and lipid reduction, especially in subjects with metabolic syndrome or type 2 diabetes. However, sample sizes are small, study designs vary considerably, and some trials report only non-significant reductions in key glycemic markers (HbA1c, fasting glucose). The mechanistic basis (enzyme inhibition, gut microbiota modulation) is supported by in vitro data but causal confirmation in humans is limited.

5.4 Gut Microbiota Modulation

Aronia melanocarpa is a fruit experiencing increasing cultivation and recognition due to its health-promoting properties. Its primary bioactive components are (poly)phenols, which are recognized for their crucial role in modulating the intestinal microbiota and exerting beneficial effects on human health.

Supporting evidence from animal and cellular models highlights the regulation of NF-κB and AMPK signaling pathways and modulation of gut microbiota as relevant mechanisms.

Evidence strength: Mechanistic animal and in vitro data are available. Human RCT data on gut microbiota outcomes specifically attributed to aronia remain preliminary, and conclusions from systematic reviews of available trials remain cautious due to heterogeneity of study designs.

5.5 Immune and Antiviral Activity

Cyanidin-3-O-galactoside from Aronia melanocarpa exhibited significantly higher antioxidant capacity compared to other individual anthocyanins. Oral administration of Aronia melanocarpa with cyanidin-3-O-glucoside and cyanidin-3-O-galactoside resulted in immunomodulatory effects on the functional activity of phagocytes in vivo.

Aronia berries were found to show potential anti-influenza activity, and one of its major components, ursolic acid, exhibited anti-COVID-19 activity, while another major compound, quercetin, has been evaluated in several clinical trials for the prevention and treatment of COVID-19. These findings are based primarily on in vitro and preliminary studies and have not been confirmed in large-scale human trials specific to aronia.

Aronia fruit extract, rich in anthocyanins, has been suggested as an effective antioxidant and immunomodulator to reduce the effects of stress and increase the body's barrier functions.

Evidence strength: Antiviral and immune-modulating effects are based largely on in vitro and animal data. Human clinical evidence in this area is sparse.

5.6 Neuroprotective Effects

Anthocyanin derived from Aronia melanocarpa fruit was found to inhibit age-related cognitive decline and diminished response capacity in senescence-accelerated mice. Additionally, mice supplemented with anthocyanins exhibited improved balance in redox systems (SOD, GSH-PX, and MDA).

Although phenolic compounds have been identified as the major active components of aronia berries, the antidiabetic, antiobesity, and neuroprotective components of these berries have not been determined unequivocally.

Evidence strength: Neuroprotective evidence for aronia is animal-only at this time. No significant human clinical trials specifically studying neurological or cognitive outcomes with aronia supplementation have been identified in the current literature.

5.7 Potential Antitumor / Anticancer Activity

Oxidative stress is found in various cancer cells, and antioxidants have been regarded as having potential value in cancer chemotherapy. Antioxidant extracts, constituents, or their semi-synthetic derivatives of aronia berries have been well documented for their potential therapeutic effects on different cancer cells, including human breast, cervical, colon, glioblastoma, liver, and lung cancer and leukemia cells.

Evidence strength: All anticancer evidence for aronia is in vitro (cell culture) or animal-based. There are no published human clinical trials establishing aronia as a cancer treatment. This area requires significant further research before clinical conclusions can be drawn.

6. Body Systems Associated with Chokeberry

• Cardiovascular system: Blood pressure modulation, lipid profile improvement, platelet aggregation reduction, endothelial function support.
• Metabolic system: Glycemic control, insulin sensitivity, lipid metabolism, adipogenic gene modulation relevant to non-alcoholic fatty liver disease.
• Gastrointestinal system: Prebiotic modulation of gut microbiota, gut barrier integrity, postprandial metabolic effects.
• Immune system: Immunomodulation via phagocyte activity, cytokine regulation, potential antiviral activity.
• Musculoskeletal system: Aronia melanocarpa extracts hindered the differentiation of osteoclasts induced by RANKL by diminishing ROS production and deactivating the JNK/ERK/p38 pathways and NF-κB-mediated signaling pathways.
• Nervous system: Potential neuroprotective effects demonstrated in animal models, particularly related to redox balance and neurotransmitter levels.
• Erythrocytes / blood: Protection of red blood cells against oxidative damage, including during exercise-induced stress.

7. Dosage Forms and Doses Reported in Studies

The following dosages have been reported in the cited peer-reviewed literature. These figures represent what has been used in specific studies and are not recommendations.

• Standardized dry extract, oral: 25 patients with metabolic syndrome were treated with aronia extract (3 × 100 mg/day) for two months in one published trial. The same dose (100 mg three times daily, totaling 300 mg/day) was used in the platelet aggregation study referenced in the clinical literature.
• Aronia juice, daily intake: A randomized, controlled, double-blinded parallel trial used 100 mL of aronia juice daily for 30 days.
• Aronia juice in athletes: The daily consumption of 150 mL of juice by rowers during a 1-month training camp was reported in one study examining oxidative damage to red blood cells.
• Aronia juice in type 2 diabetes: Three daily doses of 50 mL aronia juice, corresponding to 258 mg anthocyanins, for three months were used in a study with 35 type 2 diabetes patients.
• Ethanolic extract in healthy former smokers: 500 mg of the ethanolic extract of aronia berries was consumed daily for 12 weeks in a randomized, placebo-controlled trial on 49 healthy adult former smokers.
• Juice in healthy volunteers (antioxidant study): 11 healthy human volunteer subjects drank daily 250 mL of aronia berry juice for three weeks.
• Anthocyanin-standardized supplement (crossover trial): The standardized Aronia supplementation in a prospective, double-blinded, randomized, crossover clinical trial comprised three wild Aronia spp. and the Aronia hybrid × Sorbaronia mitschurinii, standardized to 150 mg anthocyanins daily. Participants (n = 109) were healthy men with mildly elevated total cholesterol (5.0–7.0 mM).
• Small pilot study dose: In a small pilot intervention study with ten volunteers, 100 mg of aronia extract significantly reduced peripheral glucose and blood glucose levels.
• Chokeberry juice — Indigenous health study: Participants were given 100 mL of a water-infused chokeberry juice to consume twice per day for a period of 6 weeks.

Despite results from both in vitro and in vivo studies, clinical evidence in humans remains limited, and the optimal doses, forms, and duration of supplementation are yet to be clearly established.

8. Safety Considerations and Interactions

8.1 General Safety Profile

Aronia berries have been consumed as food and as a folk remedy in Eastern Europe for centuries, and commercially in Germany and Poland for over two decades. They have no known toxicity at any reasonable consumption level. In the clinical trials that have been conducted — including studies lasting up to 12 weeks with daily consumption of 100–300 mL of aronia juice — no serious adverse effects have been reported.

The possible adverse effects of polyphenols are mostly seen with high-dose supplements or plant extracts consumed without medical supervision.

8.2 Gastrointestinal Effects

The fresh fruits of black aronia are rarely consumed due to their bitter taste from high polyphenol content. Gastrointestinal discomfort at higher intakes has been noted; the most commonly reported side effect of aronia berries is mild digestive discomfort, particularly in the first few days of use.

8.3 Drug Interactions

The simultaneous consumption of polyphenol-rich foods or extracts with some drugs may pose a risk regarding potential side effects. For instance, rhabdomyolysis developed in a patient receiving chemotherapy after the use of a herbal supplement containing Aronia melanocarpa, and sudden weakness, muscle pain, and grade 4 pancytopenia were detected. It was suggested that the aronia inhibited cytochrome P450 enzymes and allowed the drug to reach toxic levels, and the findings improved when the supplement was discontinued.

Because aronia can lower blood pressure, it can enhance the effect of antihypertensive drugs. As aronia has been shown to have some anticoagulant (blood-thinning) effects, it may affect people taking blood thinners such as warfarin. Aronia can help balance blood sugar levels, which can affect how blood sugar-lowering medications work, especially for those already taking insulin or other medications for diabetes.

The possibility of interactions of supplements with drugs should be taken into consideration, especially in individuals who use regular medications due to chronic diseases.

8.4 Cytochrome P450 Inhibition

In vitro evidence has suggested that constituents of Aronia melanocarpa can inhibit cytochrome P450 3A4 (CYP3A4) — an enzyme responsible for the metabolism of a broad range of pharmaceutical drugs. The case report of rhabdomyolysis described above (a patient receiving trabectedin chemotherapy) was attributed to this mechanism in the published literature, though the mechanistic evidence remains preliminary and based on a single case report and in vitro studies. The possibility of interactions of supplements with drugs should be taken into consideration, especially in individuals who use regular medications due to chronic diseases.

8.5 Evidence Gaps

Clinical evidence in humans remains limited, and the optimal doses, forms, and duration of supplementation are yet to be clearly established. Conclusions from meta-analyses were not entirely aligned, reflecting differences in the selection of studies, statistical approaches, and overall methodological quality. Most human studies are small (fewer than 50 participants), short in duration (2–3 months), and heterogeneous in the form and dose of aronia used, making generalized conclusions difficult.

References

• Sidor A, Gramza-Michałowska A. "Black Chokeberry Aronia Melanocarpa L.—A Qualitative Composition, Phenolic Profile and Antioxidant Potential." Molecules. 2019;24(20):3710. PMC.
• Denev P et al. "Black Chokeberry (Aronia melanocarpa) Fruits and Functional Drinks Differ Significantly in Their Chemical Composition and Antioxidant Activity." Journal of Chemistry. 2018.
• Chrubasik-Hausmann S et al. "Chokeberry (Aronia melanocarpa) as a new functional food relationship with health: an overview." ScienceDirect. 2022.
• Zhao Y et al. "A Review of Aronia melanocarpa's Phytochemical Profile, Health Benefits, and Applications in Agri-Food Systems." Foods. 2026;15(10):1627.
• Türkmen N et al. "Aronia Berry (Aronia melanocarpa L.) as a Bioactive Treasure: Insights into Its Health-Promoting Effects." ScienceDirect. 2025.
• Jurić S et al. "Aronia Melanocarpa as a Multifunctional Superberry: From Antioxidant Potential to Therapeutic and Nanotechnological Applications." PMC. 2025.
• Chen X et al. "Functional Activities and Mechanisms of Aronia melanocarpa in Our Health." PMC. 2024.
• Jabbari M et al. "Impact of a Chokeberry (Aronia melanocarpa) Supplementation on Cardiometabolic Outcomes: A Critical Systematic Review and Meta-Analysis of Randomized Controlled Trials." PMC. 2025.
• Mikkelsen MK et al. "Effects of Aronia melanocarpa on Cardiometabolic Diseases: A Systematic Review of Quasi-Design Studies and Randomized Controlled Trials." PMC. 2023.
• Hawkins J et al. "Daily supplementation with aronia melanocarpa (chokeberry) reduces blood pressure and cholesterol: a meta analysis of controlled clinical trials." Journal of Dietary Supplements. 2021;18(5).
• Broncel M et al. "Aronia melanocarpa extract reduces blood pressure, serum endothelin, lipid, and oxidative stress marker levels in patients with metabolic syndrome." PubMed. 2010.
• Sikora J et al. "Short-term supplementation with Aronia melanocarpa extract improves platelet aggregation, clotting, and fibrinolysis in patients with metabolic syndrome." PubMed. 2012.
• Sikora J et al. "Short-term supplementation with Aronia melanocarpa extract improves platelet aggregation, clotting, and fibrinolysis in patients with metabolic syndrome." PMC. 2012.
• Zare L et al. "Cellular Antioxidant Effect of an Aronia Extract and Its Polyphenolic Fractions Enriched in Proanthocyanidins, Phenolic Acids, and Anthocyanins." PMC. 2022.
• Yang SA et al. "Aronia melanocarpa Fruit Bioactive Fraction Attenuates LPS-Induced Inflammatory Response in Human Bronchial Epithelial Cells." PMC. 2020.
• Vijakumaran U et al. "Potential Benefits of Black Chokeberry (Aronia melanocarpa) Fruits and Their Constituents in Improving Human Health." PMC. 2022.
• Kellermann L et al. "Immunomodulatory Effects of Aronia Juice Polyphenols—Results of a Randomized Placebo-Controlled Human Intervention Study and Cell Culture Experiments." PMC. 2022.
• Sadowska-Bartosz I et al. "Effects of black chokeberry (Aronia melanocarpa) supplementation on oxidative stress, inflammation and gut microbiota: a systematic review of human and animal studies." British Journal of Nutrition. 2024.
• King ES et al. "Polyphenol-Rich Aronia melanocarpa Fruit Beneficially Impact Cholesterol, Glucose, and Serum and Gut Metabolites: A Randomized Clinical Trial." PMC. 2024.
• Christensen SM et al. "Aronia in the Type 2 Diabetes Treatment Regimen." PMC. 2023.
• Shen Y et al. "Anthocyanins and Type 2 Diabetes: An Update of Human Study and Clinical Trial." PMC. 2024.
• Tjønneland A et al. "Effects of Chokeberries (Aronia spp.) on Cytoprotective and Cardiometabolic Markers and Semen Quality in 109 Mildly Hypercholesterolemic Danish Men: A Prospective, Double-Blinded, Randomized, Crossover Trial." PMC. 2023.
• Jakovljevic V et al. "Standardized Aronia melanocarpa Extract as Novel Supplement against Metabolic Syndrome: A Rat Model." PMC. 2019.
• Kowalczyk E et al. "Effect of Bioactive Compound of Aronia melanocarpa on Cardiovascular System in Experimental Hypertension." PMC. 2018.
• Zare L et al. "Antioxidative and Immunomodulating Properties of Aronia melanocarpa Extract Rich in Anthocyanins." PMC. 2022.
• Stolarzewicz I et al. "Evaluation of Antioxidant and Anti-Inflammatory Activity of Anthocyanin-Rich Water-Soluble Aronia Dry Extracts." PMC. 2020.
• Rüfer CE et al. "Blood Glucose Lowering Effect by an Extract from Aronia (Aronia melanocarpa) - A Pilot Intervention Study." Current Nutrition & Food Science. 2020.
• Wikipedia. "Aronia." Accessed 2026.
• Amrani A et al. "The Impact of Black Chokeberry (Aronia melanocarpa) on Gut Microbiota and Human Health: Systematic Review and Meta-analysis of Randomized Controlled Trials in Humans." North African Journal of Food and Nutrition Research. 2025.
• PlantNative. "Black Chokeberry: Native Shrub with Edible Berries." 2026.
• ClinicalTrials.gov. "Health Effects of Traditional Indigenous Chokeberry." NCT05410327.